Drug Profile
Research programme: immunological disorders therapy - Cellzome/Graffinity
Alternative Names: Small molecule kinase modulators - Cellzome/GraffinityLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cellzome; Graffinity
- Class Small molecules
- Mechanism of Action Phosphotransferase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Immunological-disorders in Germany
- 28 Aug 2007 Preclinical development is ongoing
- 01 Feb 2006 Preclinical trials in Immunological disorders in Germany (unspecified route)